Easy Bio이지바이오

Easy Bio's profits have grown fast over recent years, but the share price has fallen about 12% over the past month and year is down 10%.

Easy Bio, a KOSDAQ-listed maker of animal feed and feed additives, reported trailing twelve-month revenue of ₩525B and net income of ₩40B to H1 2026. Its balance sheet carries significant borrowings of ₩175B against ₩48B of cash, and the stock trades at about 4.5 times earnings with a 4.6% dividend yield. The data does not include any news headlines, so recent developments are limited to filing titles.

What stands out

• Revenue rose 24.1% in 2025 to ₩477B after a 132.4% jump in 2024, while operating margin eased from 12.5% in 2023 to 9.4% in 2025.
• Trailing net margin is 7.6% and ROE is 37.8%, but liabilities are 192.2% of equity, so leverage is high.
• The stock closed at ₩5,450, near its 52-week low of ₩5,360 and well below its high of ₩8,560.
• The DCF fair value model gives a base of ₩41,095, bear ₩20,888 and bull ₩79,674; these are model outputs, not forecasts.
• Foreign ownership fell from 6.3% to 4.9% over 60 days, and foreign investors were net sellers over the last 20 days, while institutions were net buyers.

What to watch

• Next quarterly and annual filings, to see whether margins hold after the 2025 decline and whether borrowings change.
• Several 5%+ holding reports were filed in 2026, including one on 19 October; the data does not say who the holders are or what changed.
• The March 2026 change of CEO and the April corporate value-up plan; the data does not give details on either.